I en banebrytende forskning har forskerne vist at aminoglykosider (gentamicin) antibiotika kan brukes til å behandle familiær demens
De antibiotika gentamicin, neomycin, streptomycin etc are commonly used to treat bacterial infections. These are broad spectrum antibiotika tilhører aminoglykosider klasse og er spesielt aktive mot gramnegative bakterier. De virker ved å binde seg til bakterielle ribosomer og hemmer protein syntese i mottakelig bakterie.
But aminoglycosides are also known to induce mutation suppression in eukaryotes to produce full length protein. This is a lesser known function of this antibiotika which has been used in the past to treat several human diseases such as Duchenne muscular dystrophy (DMD) [2]. Now, there is report that this function may be used in treating demens også i nær fremtid.
In a paper published on 08 January 2020 in the journal, Human Molecular Genetics, the researchers of University of Kentucky have provided proof of concept that these antibiotika may be used to treat frontotemporal demens [1]. This is an exciting breakthrough in science that has potential to improve quality of lives of several people with demens.
Demens is a group of symptoms involving deterioration in ability to perform usual daily activities and is caused due to deterioration in cognitive function like memory, thinking or behavour. It is a major reason of disability and dependency among elderly people worldwide. It affects carers and families as well. According to an estimate, there are 50 million people with demens worldwide with 10 million new cases every year. Alzheimer sykdom er den vanligste formen for demens. Frontotemporal demens is the second-most common form. This is early onset in nature and affects frontal and temporal lobes of the brain.
The patients with frontotemporal demens have progressive atrophy of frontal and temporal lobes of the brain that leads to gradual deterioration of cognitive functions, language skills and personality and behavioral changes. This is heritable in nature caused by genetic mutations. As a result of these genetic mutations, the brain is unable to form a protein called progranulin. The insufficient production of progranulin in the brain in linked to this form of demens.
In their study, the University of Kentucky researchers have found that if aminoglycoside antibiotika were added to the neuronal cells with progranulin mutations in an in vitro cell culture, they skip the mutation and form full length protein. The progranulin protein level was recovered up to about 50 to 60%. This finding supports the principle that aminoglycoside (gentamicin and G418) hold the treatment possibility for such patients.
Next step would be to move forward from ”in vitro cell culture model” to ”animal model”. The mutation suppression by aminoglycosides as a therapeutic strategy to treat frontotemporal demens has come one step closer.
***
{Du kan lese den originale forskningsoppgaven ved å klikke på DOI-lenken nedenfor i listen over siterte kilder}
Source (s)
1. Kuang L., et al, 2020. Frontotemporal demens nonsense mutation of progranulin rescued by aminoglycosides. Human Molecular Genetics, ddz280. DOI: https://doi.org/10.1093/hmg/ddz280
2. Malik V., et al, 2010. Aminoglykosid-indusert mutasjonsundertrykkelse (stopp kodon readthrough) som en terapeutisk strategi for Duchenne muskeldystrofi. Therapeutic Advances in Neurological Disorders (2010) 3(6) 379389. DOI: https://doi.org/10.1177/1756285610388693
***
